[Is it feasible to develop a 5-HT basis for the treatment of depression?].
Hamon
M
M
Unité de l'INSERM, Hôpital de la Salpêtrière, Paris.
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D017660:Autoreceptors / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D006801:Humans; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology*; D012701:Serotonin / Q000502:physiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D017660:Autoreceptors; D011985:Receptors, Serotonin; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors